WTG
REGN icon

West Tower Group’s Regeneron Pharmaceuticals REGN Stock Holding History

West Tower Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-184
Closed -$162K – 426
2023
Q4 		$162K Buy
+184
New +$152K 0.33% 43
2023
Q3 		– Sell
-232
Closed -$167K – 775
2023
Q2 		$167K Buy
+232
New +$179K 0.12% 75

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

West Tower Group's REGN Position: Q1 2024 in Review

West Tower Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 184 shares — an estimated $162K sold.

West Tower Group first reported a position in REGN in Q2 2023 and held it in 2 quarters. The position peaked at $167K in Q2 2023. 1,309 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • West Tower Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • West Tower Group sold 184 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $162K.
  • West Tower Group first reported a position in Regeneron Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • West Tower Group's Regeneron Pharmaceuticals position peaked at $167K in Q2 2023.
  • 1,309 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on West Tower Group's 13F filing for Q1 2024, filed 14 May 2024.